Table 4. Molecular abnormalities matching a molecularly targeted agent available in the frame of the SHIVA trial.

		Molecular pathway
Tumour type and histology	N (%) (n=95)	PI3K/AKT/mTOR	Hormonal	MAPK
Breast adenocarcinoma	9 (9%)		AR+
	2 (2%)	PI3KCA mutation (Glu545Lys)
	2 (2%)	PI3KCA mutation (His1047Arg)
	1 (1%)	PTEN deletion
Ovarian adenocarcinoma	3 (3%)		ER±PR+
	1 (1%)		AR+
	1 (1%)	Gains of AKT2, mTOR, RPTOR
Lung adenocarcinoma	1 (1%)			HER2 amplification
	1 (1%)	STK11 loss+mutation (Asp194Leu)
	1 (1%)	PTEN loss
	1 (1%)	AKT1 amplification
Cervix squamous cell carcinoma	1 (1%)	PI3KCA mutation (Glu545Lys) +
		STK11 loss+mutation (Phe345Leu)
	1 (1%)		ER+
Cervix adenocarcinoma	2 (2%)		ER+
HNSCC	1 (1%)	PI3KCA mutation (Glu545Lys)
	1 (1%)	Gains of AKT1, AKT2, PI3KCB, RICTOR Loss of STK11
Urothelial carcinoma	1 (1%)		ER+
Anal squamous cell carcinoma	1 (1%)	PI3KCA mutation (Glu545Lys)
Mesothelioma	1 (1%)		AR+
Lung small cell carcinoma	1 (1%)		AR+
Soft tissue sarcoma	1 (1%)		AR+
Uterine leiomyosarcoma	1 (1%)		PR+
Uterine sarcoma	1 (1%)			PDGFRA activation
Endometrial adenocarcinoma	1 (1%)		AR+
Merckel cell tumour	1 (1%)		ER+
Total	38 (40%)	13 (13%)	23 (24%)	2 (2%)

Abbreviations: AR=androgen receptor; ER=oestrogen receptor; HNSCC=head and neck squamous cell carcinoma; mTOR=mammalian Target Of Rapamycin; PR=progesterone receptor; SCLC=small cell lung cancer.